Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 3 Randomized, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of MK-0616 in Reducing Major Adverse Cardiovascular Events in Participants at High Cardiovascular Risk

Next Previous
Trial Profile

Phase 3 Randomized, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of MK-0616 in Reducing Major Adverse Cardiovascular Events in Participants at High Cardiovascular Risk

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 29 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Enlicitide decanoate (Primary)
  • Indications Ischaemic stroke; Myocardial infarction
  • Focus Registrational; Therapeutic Use
  • Acronyms CORALreef Outcomes
  • Sponsors Merck Sharp & Dohme

Most Recent Events

  • 15 Oct 2023 Status changed from not yet recruiting to recruiting.
  • 28 Aug 2023 New trial record
  • 25 Aug 2023 According to Merck & Co media release, the company plans to initiate this study by the end of 2023; MK0616 program plans to enroll approximately 17,000 participants across three global studies (CORALreef Lipids, CORALreef Outcome and CORALreef HeFH)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top